



ASX Announcement

Change to financial year end

SYDNEY Australia: 29 September 2011 – Sunshine Heart, Inc. (ASX: SHC) (**Sunshine Heart**), today announced that it will be changing the date of its financial year end from 30 June to 31 December, effective from 1 July 2011.

The change in financial year end will not affect Sunshine Heart's financial year ended 30 June 2011. Sunshine Heart is currently finalising its annual report for the 12 months ended 30 June 2011 and will report these results in accordance with ASX reporting times. Sunshine Heart will also prepare a further financial report covering the six month transitional period 1 July 2011 to 31 December 2011. Annual reports after that will be prepared for a 12 month period from 1 January to 31 December for each subsequent year.

About the C-Pulse Heart Assist System

C-Pulse Heart Assist System utilizes the proven scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Operating outside the patient's bloodstream, the novel extra-aortic approach of the C-Pulse technology offers greater flexibility allowing patients to disconnect as necessary or desired. The C-Pulse Heart Assist's potential benefits may help reverse the heart failure process or maintain the patient's current condition, thereby preventing the need for later stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants.

About Sunshine Heart

Sunshine Heart (ASX: SHC) is a global medical device company committed to novel cardiac and coronary therapy. The company is currently developing the C-Pulse[®] Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-Pulse is designed to relieve the symptoms of heart failure through the use of counter-pulsation technology by enabling an increase in cardiac output, an increase in coronary blood flow, and a reduction in the heart's pumping load. The company has received approval from the U.S. Food and Drug Administration to conduct a U.S. feasibility clinical trial with the C-Pulse System. Sunshine Heart is a Delaware-based corporation headquartered in Minneapolis, MN, with a subsidiary presence in Australia. The company has been listed on the Australian Securities Exchange (ASX) since September 2004. For more information, please visit www.sunshineheart.com.

For further information, please contact:

Dave Rosa	Jeff Mathiesen
Chief Executive Officer	Chief Financial Officer
+1 952 345 4200	+1 952 345 4200